Blog

The latest thoughts from Medicines Law & Policy partners.

The European Commission’s proposal for an EU wide compulsory licensing mechanism

In 2006 the European Generics Association was seeking clarification from the European Commission on whether generic versions of oseltamivir (Tamiflu) could be supplied to...

Medicines Law & Policy statement at WHO PABS negotiations (IGWG 5)

Co-chairs, Thank you for the opportunity to say a few words.  My comments address issues related to technology transfer (TT), a topic we have been...

Pharmaceutical Accountability Foundation is taking AbbVie to court over excessive pricing of Humira –...

On 21 February, the Dutch Pharmaceutical Accountability Foundation (PAF) took the bold step to take AbbVie to court, claiming the company’s pricing policy had...

Advanced Purchase Agreements for Covid-19 Vaccines: Do they ensure Global Public Good?

Advanced Purchase Agreements (APAs) were part of a strategy to provide upfront financing for Covid-19 vaccines and to accelerate their development and availability. Since...

Worldwide licensing of pandemic technologies is already current practice. The Pandemic Accord should protect...

The negotiations for a WHO pandemic accord are still in full swing this week. Talks are taking place behind closed doors, but it is...

We need a Global Vaccines Taskforce, not just a British or European one

The European Commission has been heavily criticised for its performance over Covid-19 vaccine supply to European Union Member States. Despite the urgency of the...

Lessons for a pandemic preparedness treaty from previous successes and failures with treaty-based technology...

This post can also be downloaded as a PDF here. 1.      Introduction Scaling-up production of new vaccines to provide many billions of doses on a time-scale...

European Pharmaceutical Legislation Needs Exceptions to Data and Market Exclusivity to Protect European Patients...

On 11 May 2018, US President Trump announced his plans to lower drug prices in America. Under the banner "American Patients First" he outlined...

New reports offer evidence for extending the WTO Decision on TRIPS to Covid-19 therapeutics...

In February 2024, the 13th World Trade Organization (WTO) Ministerial Conference will take place. WTO Members are expected to decide whether to extend the...

New WHO-UNITAID briefing paper: Improving Access to Covid-19 Treatments

A new briefing paper based on Medicines Law & Policy research outlines the legal instruments available for countries seeking to access key therapeutics to...